Inhaled corticosteroids: managing side effects Inhaled corticosteroids are commonly prescribed but need careful management to minimise the risk of side effects.…
Generic prescribing is not appropriate for inhaled drugsThe UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clini…
Oxygen therapy reduces dyspnoea in COPD patients with mild disease Continuous oxygen during exertion, but not short-burst therapy, significantly reduces dyspnoea in patients with mild chronic obstructive pulmonary disease, researchers find.…
2014: The Pharmaceutical Journal’s news in review Looking back at some of the biggest news stories from the past year. …
Targeting disease in the developing world A new report by the Access to Medicine Index finds that pharmaceutical companies influence access to medicines in developing countries through the development of innovative and adapted products, operating equitable pricing strategies and building local capacity.…
Pharmacy support for COPD patients improves medicine-taking behaviour A study published in the International Journal of Pharmacy Practice suggests that a community pharmacy COPD service improves the way patients take their medicines and is cost effective.…
Pharmacy COPD-screening could save the NHS £264m Community pharmacies can help identify undiagnosed cases of chronic obstructive pulmonary disease at an early stage, which could result in savings of around £264m per year, a pilot study suggests.…
Clinical Pharmacist’s monthly news round-up: the top 10 in October 2014What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month……
Combination inhaler Anoro Ellipta launched for COPD Anoro Ellipta, a novel inhaler containing a long-acting muscarinic receptor antagonist and a selective long-acting beta-2 adrenergic receptor agonist, may find a limited place in therapy.…
Paradoxical bronchoconstriction occurs in 5% of COPD patients treated with beta-2-agonists African–American patients with COPD are more likely to be affected by therapy-induced bronchoconstriction, study suggests.…
